News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XOMA (US) LLC (XOMA) Selects Non-Infectious Anterior Scleritis as Next Indication in Gevokizumab Proof-of-Concept Program



1/2/2013 9:10:56 AM

BERKELEY, Calif., Dec. 31, 2012 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced it has selected active non-infectious anterior scleritis, which is the inflammation of the sclera (the fibrous white membrane surrounding the eyeball excluding the cornea), as the third indication in XOMA's gevokizumab proof-of-concept program. The Company is working with the National Eye Institute ("NEI"), one of the U.S. National Institutes of Health, on designing the protocol for this study.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES